Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation.

Kane JM 3rd, Magliocco A, Zhang Q, Wang D, Klimowicz A, Harris J, Simko J, DeLaney T, Kraybill W, Kirsch DG.

Sarcoma. 2018 Feb 28;2018:8310950. doi: 10.1155/2018/8310950. eCollection 2018.

2.

A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Yu PY, Balkhi MY, Ladner KJ, Alder H, Yu L, Mo X, Kraybill WG, Guttridge DC, Iwenofu OH.

Lab Invest. 2016 Apr;96(4):481-91. doi: 10.1038/labinvest.2015.168. Epub 2016 Feb 15.

3.

Contemporary approaches to sarcoma.

Kraybill WG, Pollock RE.

J Surg Oncol. 2015 Apr;111(5):489. doi: 10.1002/jso.23875. No abstract available.

PMID:
25810082
4.

Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB; MSLT Group.

N Engl J Med. 2014 Feb 13;370(7):599-609. doi: 10.1056/NEJMoa1310460.

5.

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC.

Sci Signal. 2013 Jul 30;6(286):ra63. doi: 10.1126/scisignal.2004177. Erratum in: Sci Signal. 2013 Sep 10;6(292):er6. Balkhi, Mumtaz Y [corrected to Balkhi, M Y].

6.

The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.

Hemminger JA, Ewart Toland A, Scharschmidt TJ, Mayerson JL, Kraybill WG, Guttridge DC, Iwenofu OH.

Mod Pathol. 2013 Feb;26(2):282-8. doi: 10.1038/modpathol.2012.133. Epub 2012 Aug 31.

7.

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cochran AJ, Faries MB, Morton DL.

Ann Surg Oncol. 2012 Aug;19(8):2547-55. doi: 10.1245/s10434-012-2398-z. Epub 2012 May 31.

8.

Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330.

Kane JM 3rd, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, Delaney TF, Wang D, Curran WJ, Eisenberg BL.

Sarcoma. 2012;2012:659485. doi: 10.1155/2012/659485. Epub 2012 Apr 24.

9.

Prognostic factors and staging for soft tissue sarcomas: an update.

Jones NB, Iwenofu H, Scharschmidt T, Kraybill W.

Surg Oncol Clin N Am. 2012 Apr;21(2):187-200. doi: 10.1016/j.soc.2011.12.003. Epub 2012 Jan 9.

PMID:
22365514
10.

Patient surveillance after treatment for soft-tissue sarcoma.

Johnson FE, Sakata K, Sarkar S, Audisio RA, Kraybill WG, Gibbs JF, Beitler AL, Virgo KS.

Int J Oncol. 2011 Jan;38(1):233-9.

PMID:
21109945
11.

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B.

Cancer. 2010 Oct 1;116(19):4613-21. doi: 10.1002/cncr.25350.

12.

Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans.

Meguerditchian AN, Wang J, Lema B, Kraybill WG, Zeitouni NC, Kane JM 3rd.

Am J Clin Oncol. 2010 Jun;33(3):300-3. doi: 10.1097/COC.0b013e3181aaca87.

PMID:
19858696
13.

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.

Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT.

Cancer. 2009 Dec 15;115(24):5836-44. doi: 10.1002/cncr.24627.

14.

Soft tissue sarcomas: current management and future directions.

Kenney RJ, Cheney R, Stull MA, Kraybill W.

Surg Clin North Am. 2009 Feb;89(1):235-47, x. doi: 10.1016/j.suc.2008.09.020. Review.

PMID:
19186238
15.

Alveolar soft part sarcoma metastatic to small bowel mucosa causing polyposis and intussuseption.

Sabel MS, Gibbs JF, Litwin A, McGrath B, Kraybill WB, Brooks JJ.

Sarcoma. 2001;5(3):133-7. doi: 10.1080/13577140120048584.

16.

The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases.

Kane JM, Finley JW, Driscoll D, Kraybill WG, Gibbs JF.

Sarcoma. 2002;6(2):69-73. doi: 10.1080/1357714021000022168.

17.

Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy.

Smith R, Pak Y, Kraybill W, Kane JM 3rd.

Eur J Surg Oncol. 2009 Apr;35(4):356-61. doi: 10.1016/j.ejso.2008.01.004. Epub 2008 Feb 21.

PMID:
18294807
18.

Core biopsy for diagnosis and tissue procurement.

Kenney R, Cheney R, Kraybill W.

J Surg Oncol. 2008 Apr 1;97(5):374-5. doi: 10.1002/jso.20955. No abstract available.

PMID:
18163460
19.

Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin.

Xu Y, Choi J, Hylander B, Sen A, Evans SS, Kraybill WG, Repasky EA.

Int J Hyperthermia. 2007 Sep;23(6):513-27.

PMID:
17952765
20.

Soft tissue sarcoma.

Demetri GD, Baker LH, Benjamin RS, Casper ES, Conrad EU 3rd, D'Amato GZ, DeLaney TF, Ettinger DS, Heck R Jr, Heslin MJ, Hutchinson RJ, Jacobs CD, Kiel K, Kraybill WG, Letson GD, O'Donnell RJ, Paz IB, Pfeifer J, Pollock RE, Randall RL, Sasson AR, Schupak KD, Tyler DS, von Mehren M, Wayne J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2007 Apr;5(4):364-99. No abstract available.

PMID:
17442230
21.

Seminars in patient rehabilitation: editorial.

Kraybill WG, Huang M.

J Surg Oncol. 2007 Apr 1;95(5):359-60. No abstract available.

PMID:
17372932
22.

Adjuvant therapy for extremity sarcomas.

Schlieman M, Smith R, Kraybill WG.

Curr Treat Options Oncol. 2006 Nov;7(6):456-63. Review.

PMID:
17032558
23.

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL, Tyler DS; American College of Surgeons Oncology Group Trial Z0020.

J Clin Oncol. 2006 Sep 1;24(25):4196-201.

PMID:
16943537
24.

Melanoma.

Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Aug;4(7):666-84. No abstract available.

PMID:
16884669
25.

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B; Radiation Therapy Oncology Group Trial 9514.

J Clin Oncol. 2006 Feb 1;24(4):619-25.

PMID:
16446334
26.

American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.

Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane JM 3rd.

Ann Surg Oncol. 2006 Feb;13(2):198-204. Epub 2006 Jan 19.

PMID:
16418885
27.

Developments in the management of extremity soft tissue sarcomas.

Palesty JA, Kraybill WG.

Cancer Invest. 2005;23(8):692-9. Review.

PMID:
16377588
28.

Retiform hemangioendothelioma: a case report and review of the literature.

Tan D, Kraybill W, Cheney RT, Khoury T.

J Cutan Pathol. 2005 Oct;32(9):634-7.

PMID:
16176302
29.

The anti-tumor effect of interleukin-12 is enhanced by mild (fever-range) thermal therapy.

Pritchard MT, Wolf SF, Kraybill WF, Repasky EA.

Immunol Invest. 2005;34(3):361-80.

PMID:
16136786
30.

Radical operations for soft tissue sarcomas.

Kane JM 3rd, Kraybill WG.

Surg Oncol Clin N Am. 2005 Jul;14(3):633-48, viii. Review. No abstract available.

PMID:
15978433
31.

Long-term management of patients after potentially curative treatment of extremity soft tissue sarcoma: practice patterns of members of the Society of Surgical Oncology.

Johnson FE, Sakata K, Kraybill WG, Gibbs JF, Beitler AL, Sarkar S, Audisio RA, Virgo KS.

Surg Oncol. 2005 Jul;14(1):33-40. Review.

PMID:
15777888
32.

Soft tissue sarcoma clinical practice guidelines in oncology.

Demetri GD, Baker LH, Beech D, Benjamin R, Casper ES, Conrad EU 3rd, DeLaney TF, Ettinger DS, Heslin MJ, Hutchinson RJ, Kiel K, Kraybill WG, Letson GD, Neff J, O'Donnell RJ, Paz IB, Pollock RE, Randall RL, Schupak KD, Tyler DS, von Mehren M, Wayne J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Mar;3(2):158-94. No abstract available.

33.

Costs of follow-up after potentially curative treatment for extremity soft-tissue sarcoma.

Goel A, Christy ME, Virgo KS, Kraybill WG, Johnson FE.

Int J Oncol. 2004 Aug;25(2):429-35.

PMID:
15254741
34.

Palliative surgery of soft tissue sarcoma.

Sheldon DG, James TA, Kraybill WG.

Surg Oncol Clin N Am. 2004 Jul;13(3):531-41, ix. Review.

PMID:
15236734
35.

The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma.

Hinrichs CS, Gibbs JF, Driscoll D, Kepner JL, Wilkinson NW, Edge SB, Fassl KA, Muir R, Kraybill WG.

J Surg Oncol. 2004 Mar 15;85(4):187-92.

PMID:
14991874
36.

The prognostic significance of margin width for extremity and trunk sarcoma.

McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL, Kraybill WG.

J Surg Oncol. 2004 Feb;85(2):68-76.

PMID:
14755506
37.

Protocols for simulating the thermal component of fever: preclinical and clinical experience.

Pritchard MT, Ostberg JR, Evans SS, Burd R, Kraybill W, Bull JM, Repasky EA.

Methods. 2004 Jan;32(1):54-62.

PMID:
14624878
38.

Diagnostic challenges in patients with tumors: case 1. Gossypiboma (foreign body) manifesting 30 years after laparotomy.

Rajput A, Loud PA, Gibbs JF, Kraybill WG.

J Clin Oncol. 2003 Oct 1;21(19):3700-1. No abstract available.

PMID:
14512403
39.

Clinical trials and soft tissue sarcomas.

Rajput A, Kraybill WG.

Surg Oncol Clin N Am. 2003 Apr;12(2):485-97. Review.

PMID:
12916465
40.

Extremity soft tissue sarcoma patient follow-up: tumor grade and size affect surveillance strategies after potentially curative surgery.

Sakata K, Johnson FE, Beitler AL, Kraybill WG, Virgo KS.

Int J Oncol. 2003 Jun;22(6):1335-43.

PMID:
12739002
41.

How surgeon age affects surveillance strategies for extremity soft tissue sarcoma patients after potentially curative treatment.

Sakata K, Beitler AL, Gibbs JF, Kraybill WG, Virgo KS, Johnson FE.

J Surg Res. 2002 Dec;108(2):227-34.

PMID:
12505046
42.

A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models.

Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA.

Int J Hyperthermia. 2002 May-Jun;18(3):253-66.

PMID:
12028640
43.

Radiation Therapy Oncology Group. Research Plan 2002-2006. Sarcoma Committee.

Eisenburg BL, Alektiar K, Ballo M, DeLaney TF, Ettinger D, Harmon D, Harris J, Joyce M, Kraybill WG, Leider S, Lucas D, Peterson I, Pollock RE, Pritchard D, Schwartz HS, Yasko AW, Pisters PT, Patel SR, watson J; Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):53-5. No abstract available.

PMID:
11641015
44.

Local excision of rectal carcinoma.

Chorost MI, Petrelli NJ, McKenna M, Kraybill WG, Rodriguez-Bigas MA.

Am Surg. 2001 Aug;67(8):774-9.

PMID:
11510582
45.

Clear cell sarcoma: the Roswell Park experience.

Finley JW, Hanypsiak B, McGrath B, Kraybill W, Gibbs JF.

J Surg Oncol. 2001 May;77(1):16-20. Review.

PMID:
11344475
46.

Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade.

Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B.

Ann Surg Oncol. 2001 Apr;8(3):260-7.

PMID:
11314944
47.

Malignant fibrous histiocytoma: an institutional review.

Gibbs JF, Huang PP, Lee RJ, McGrath B, Brooks J, McKinley B, Driscoll D, Kraybill WG.

Cancer Invest. 2001;19(1):23-7.

PMID:
11291552
48.

Risk factors for nodal recurrence after lymphadenectomy for melanoma.

Pidhorecky I, Lee RJ, Proulx G, Kollmorgen DR, Jia C, Driscoll DL, Kraybill WG, Gibbs JF.

Ann Surg Oncol. 2001 Mar;8(2):109-15.

PMID:
11258774
49.

Large, deep high-grade extremity sarcomas: when is a myocutaneous flap reconstruction necessary?

Kane JM 3rd, Gibbs JF, McGrath BE, Loree TR, Kraybill WG.

Surg Oncol. 1999 Dec;8(4):205-10. Review.

PMID:
11128834
50.

Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF.

Ann Surg Oncol. 2000 Oct;7(9):705-12. Review.

PMID:
11034250

Supplemental Content

Loading ...
Support Center